Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. (the "Company") on May 4, 2026. The report details a material definitive agreement entered into on the same date involving Citius Oncology, Inc., the Company's majority-owned subsidiary, in connection with an equity financing transaction and a new debt facility.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial data point disclosed is the outstanding principal balance of a specific intercompany promissory note.
- Promissory Note Principal: $3,800,111 (Original amount issued August 16, 2024).
- Conversion Price: $0.90 per share (for voluntary conversion of the note).
Material Changes
The Company executed a Third Amendment to the Promissory Note held by Citius Oncology. Key changes include:
- Maturity Date Adjustment: The note is now payable 91 days after Citius Oncology's senior debt is fully paid and the related loan agreement is terminated, aligning with a new subordination agreement.
- Elimination of Triggers: All prior maturity triggers related to capital raises, debt/equity issuances, or royalty-backed monetizations have been removed.
- Prepayment Restriction: Cash prepayment of the note is prohibited prior to the new maturity date.
- Voluntary Conversion: A new feature allows the Company to convert all or part of the principal into common stock at $0.90 per share, subject to Citius Oncology's approval.
Outlook, Risks, and Management Commentary
The amendment was executed to facilitate Citius Oncology's equity financing and debt facility. The filing does not contain forward-looking guidance, specific risk factors beyond the terms of the amendment, or management commentary regarding future operational performance. The text notes that the description of the amendment is qualified by reference to the full text of Exhibit 10.1.
Investor Verification Checklist
- Verify the status and terms of Citius Oncology's new senior debt facility and equity financing.
- Review the full text of the Third Amendment to Promissory Note (Exhibit 10.1) for detailed covenants.
- Assess the impact of the 91-day post-senior-debt maturity timeline on the Company's liquidity and balance sheet.
- Confirm the current share price relative to the $0.90 conversion price to evaluate the likelihood of conversion.